164 related articles for article (PubMed ID: 2208110)
1. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R
Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
3. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
4. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Grant S; Bhalla K; Arlin Z; Howe CW
Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
[TBL] [Abstract][Full Text] [Related]
5. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
6. A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.
White JC; Capizzi RL
Cancer Res; 1991 May; 51(10):2559-65. PubMed ID: 2021937
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
8. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
9. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
10. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
Jaramillo AC; Bergman AM; Comijn EM; Jansen G; Kaspers GJL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1346. PubMed ID: 32727269
[TBL] [Abstract][Full Text] [Related]
11. 1-beta-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells.
Kharbanda S; Emoto Y; Kisaki H; Saleem A; Kufe D
Mol Pharmacol; 1994 Jul; 46(1):67-72. PubMed ID: 8058058
[TBL] [Abstract][Full Text] [Related]
12. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Colly LP; Peters WG; Willemze R
Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
[TBL] [Abstract][Full Text] [Related]
14. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
15. Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
Balzarini J; De Clercq E
Mol Pharmacol; 1983 Jan; 23(1):175-81. PubMed ID: 6306422
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
Grant S; Turner A; Nelms P; Yanovich S
Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
[TBL] [Abstract][Full Text] [Related]
17. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
[TBL] [Abstract][Full Text] [Related]
19. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
White JC; Hines LH
Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
